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Abstract
Background—Several methods are recommended equally strongly for colorectal cancer 
screening in average-risk persons. Risk stratification would enable tailoring of screening within 
this group, with less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and 
colonoscopy for higher-risk persons.
Objective—To create a risk index for advanced neoplasia (colorectal cancer and adenomas or 
serrated polyps ≥1.0 cm, villous histology, or high-grade dysplasia) anywhere in the colorectum, 
using the most common risk factors for colorectal neoplasia.
Design—Cross-sectional study.
Setting—Multiple endoscopy units, primarily in the Midwest.
Patients—Persons aged 50 to 80 years undergoing initial screening colonoscopy (December 
2004 to September 2011).
Measurements—Derivation and validation of a risk index based on points from regression 
coefficients for age, sex, waist circumference, cigarette smoking, and family history of colorectal 
cancer.
Results—Among 2993 persons in the derivation set, prevalence of advanced neoplasia was 9.4%. 
Risks for advanced neoplasia in persons at very low, low, intermediate, and high risk were 1.92% 
(95% CI, 0.63% to 4.43%), 4.88% (CI, 3.79% to 6.18%), 9.93% (CI, 8.09% to 12.0%), and 24.9% 
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(CI, 21.1% to 29.1%), respectively (P < 0.001). Sigmoidoscopy to the descending colon in the 
low-risk groups would have detected 51 of 70 (73% [CI, 61% to 83%]) advanced neoplasms. 
Among 1467 persons in the validation set, corresponding risks for advanced neoplasia were 1.65% 
(CI, 0.20% to 5.84%), 3.31% (CI, 2.08% to 4.97%), 10.9% (CI, 8.26% to 14.1%), and 22.3% (CI, 
16.9% to 28.5%), respectively (P < 0.001). Sigmoidoscopy would have detected 21 of 24 (87.5% 
[CI, 68% to 97%]) advanced neoplasms.
Limitations—Split-sample validation; results apply to first-time screening.
Conclusion—This index stratifies risk for advanced neoplasia among average-risk persons by 
identifying lower-risk groups for which noncolonoscopy strategies may be effective and efficient 
and a higher-risk group for which colonoscopy may be preferred.
Keywords
colorectal cancer; cancer screening; risk stratification
In the United States, colorectal cancer is a significant cause of morbidity and mortality 
among men and women, accounting for nearly 140 000 new cases and 55 000 deaths per 
year (1). The natural history of colorectal neoplasia, which usually involves a slow 
progression from precancerous polyp to cancer, lends itself to screening. Screening for 
colorectal cancer with any of several tests and strategies has been found to be effective (2–3) 
and cost-effective (4–7) and is supported by guidelines from several organizations (8–10). 
Foremost among them is the U.S. Preventive Services Task Force (10), which recommends 
any of several screening tests and strategies with no preference for any single strategy based 
on direct evidence and quantitative modeling (11–12).
Despite the favorable biology, test options, and evidence to support screening, it is 
underused, costly, and inefficient. Nearly 22 million U.S. residents aged 50 to 75 years have 
never been screened, and just 60% to 65% have had lower endoscopy of any kind for any 
reason within the past 10 years (13). Although screening is cost-effective, it is estimated to 
cost billions of dollars per year (14–15). In addition to its high total cost, screening is 
conducted inefficiently; low-risk persons may receive colonoscopy with low yield and little 
benefit, and high-risk persons may receive noninvasive testing with missed opportunity for 
benefit.
Tailoring of colorectal cancer screening based on risk could improve the overall uptake and 
efficiency of screening. Among average-risk persons not current with screening, knowledge 
of their personal risk for colorectal cancer or advanced neoplasia might affect how they 
choose to be screened. For lower-risk persons within the average-risk group, screening could 
be done with stool-based occult blood tests or sigmoidoscopy (or both), which are less 
invasive, less risky, and less costly than colonoscopy. For higher-risk persons, initial 
colonoscopy might be the preferred test.
Several risk prediction models for either colorectal cancer (16–18) or advanced neoplasia 
(19–24) (colorectal cancer plus advanced, precancerous polyps) may not be clinically useful 
for several reasons. Models predicting risk for advanced neoplasia either show limited 
performance in risk stratification (that is, "high risk" and "low risk" are not far from average 
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risk) or are based on populations with unclear generalizability to the U.S. population. 
Further, all models are limited in their degree of validation. In this study, we developed and 
validated a risk stratification tool for advanced neoplasia anywhere in the colon and rectum 
using the most commonly identified risk factors for colorectal cancer and advanced 
adenomas. We included advanced adenomas because they are believed to be immediate 
precursor lesions to most colorectal cancer (25), even though their natural history is 
unknown.
Methods
This study was conducted at the Indiana University Medical Center in Indianapolis, Indiana, 
and was approved by the Institutional Review Board of Indiana University at Indianapolis. 
We report methods and results in accordance with the STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) and TRIPOD (Transparent Reporting 
of a multivariable prediction model for Individual Prognosis Or Diagnosis) guidelines (26–
27). Between December 2004 and September 2011, we enrolled consecutive eligible and 
consenting persons aged 50 to 80 years who were scheduled to have their first screening 
colonoscopy. We initially recruited patients from endoscopy units participating in either of 2 
company-based colorectal cancer prevention programs, one of which was based in central 
Indiana and the other in northeastern Ohio. Because of low uptake in these programs, we 
expanded recruitment to include general endoscopy practices and units within central 
Indiana, including those affiliated with Indiana University Medical Center. At all sites and 
throughout the study, we excluded persons with inflammatory bowel disease, those with a 
high-risk family history (polyposis or nonpolyposis colorectal cancer syndrome), and those 
reporting a history of polyps that required follow-up colonoscopy.
Before having colonoscopy, enrolled participants were asked to complete a comprehensive 
survey that asked about candidate risk factors, including family history; sociodemographic 
factors; and lifestyle factors, including previous and current cigarette smoking. Participants 
were also asked to measure and record current height, weight, and waist and hip 
circumference; a tape measure was provided for the circumferential measurements. On the 
day of their screening colonoscopy, participants' physical measures were collected by 
medical personnel just before the procedure. In analysis, physical measures recorded by 
medical personnel were used unless they were unavailable, in which case self-reported 
measures were used.
All surveys were reviewed for completeness by trained study personnel, who contacted 
participants by telephone for clarification or completion of survey items. Colonoscopy and 
pathology reports were reviewed and coded by trained personnel who were blinded to survey 
information. The most advanced findings in the colorectum were coded for both proximal 
(which includes the splenic flexure) and distal segments. Colonoscopies with no pathology 
report were assumed to show no neoplasia, provided that the colonoscopy report did not 
specify that a tissue specimen had been obtained (biopsy or polypectomy). After review, 
completion, and coding, all data were scanned into a deidentified database with unique 
identifier numbers.
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Study sample size was based on both prevalence of advanced neoplasia from a previous 
study of screening colonoscopy among average-risk persons (28) and a goal of ensuring an 
adequate number of persons with advanced neoplasia for derivation and split-sample 
validation. In analysis, a stratified random sample comprising two thirds of the original 
sample was obtained using PROC SURVEYSELECT in SAS, version 9.3 (SAS Institute). 
Strata were created using the following variables: advanced neoplasia, sex, family history of 
cancer, and body mass index (BMI). Participants in this data set were used as the derivation 
set, and the other one third of participants were used as a validation set. The data set was 
divided in this way to ensure a random but equal distribution of sex and most advanced 
findings. The goal of the analysis was to determine model performance using 5 factors that 
are most commonly associated with colorectal neoplasia in the published literature: age, sex, 
cigarette smoking, body fat, and a family history of colorectal cancer. For cigarette smoking, 
which was measured in pack-years, we considered different cutoffs to categorize exposure. 
For measures of body fat, we considered BMI, waist circumference, and waist-to-hip ratio. 
Categories for measures of body fat were determined a priori based on published literature 
that related each physical factor to risk for either colorectal cancer or advanced adenoma 
(29–31). For family history of colorectal cancer, we considered first-degree relatives only 
and both first- and second-degree relatives, and we considered ages for both categories. For 
family history, cigarette smoking, and measures of body fat, we used age- and sex-adjusted 
logistic regression models to quantify the most discriminating variable (in the case of body 
fat) or to compare different ways of categorizing them, as determined by the Wald test and 
odds ratio for the variable itself and the omnibus likelihood ratio test for the model (32) 
(Appendix Table 1). The outcome (dependent) variable was advanced neoplasia, which 
included adenocarcinoma of the colon or rectum, a tubular adenoma or sessile serrated 
adenoma or polyp with a greatest dimension of at least 1 cm, or an adenomatous polyp with 
villous histology or high-grade dysplasia.
We used statistical metrics and clinical judgment to choose the optimal format for cigarette 
smoking, family history of colorectal cancer, and body fat measurement. We then included 
them in a model along with age and sex and determined performance of the full model in the 
derivation set by measuring calibration with the Hosmer–Lemeshow test and discrimination 
with the c-statistic (32). The log-odds coefficients from each variable were subsequently 
incorporated into a points system, an approach described by Sullivan and colleagues (33). 
Coefficients were translated into risk categories for advanced neoplasia, with 0 points 
representing the lowest-risk group for each variable. Points were rounded to the nearest 
integer and were scaled such that a single point was equivalent to the increase in risk for 
advanced neoplasia associated with a 5-year increase in age (Appendix Table 2). On the 
basis of previous work (34), we planned to create risk categories by collapsing scores with 
clinically similar risk estimates. We used a chi-square test for trend for risk for (or 
prevalence of) advanced neoplasia across categories, and we tested performance of the 
model and the risk score classification table by using the same cutoffs and categories on the 
validation set, which contained the remaining one third of the study participants. SAS, 
version 9.3, was used for all analyses. For each risk group within the derivation and 
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validation sets, we calculated likelihood ratios, defined as the proportion of persons with 
advanced neoplasia divided by the proportion without.
Results
A total of 4500 eligible consenting persons were enrolled into the study between December 
2004 and September 2011. Demographic and clinical features of the derivation (n = 3025) 
and validation (n = 1475) sets were similar, including the proportion of participants with 
complete data who were used in subsequent analyses (Table 1). Ninety-four percent of 
persons in the cohort were white.
Results of age- and sex-adjusted models for family history of colorectal cancer, cigarette 
smoking, and body fat measurement are shown in Table 2 and are based on the derivation 
set. The presence versus absence of 1 or more first-degree relatives with colorectal cancer 
was used on the basis of practical consideration of reporting accuracy, statistical metrics 
(Appendix Table 1), and published literature (35). For cigarette smoking, cutoffs of 0 and 30 
pack-years were chosen on the basis of the number of categories and statistical 
discrimination (Appendix Table 1). Among the physical measures of body fat, waist 
circumference, which was categorized as small (<95.0 cm for men or <87.9 cm for women) 
(29), medium, or large ( 119.9 cm for men or ≥110.0 cm for women), was more 
discriminating than either BMI or waist-to-hip ratio.
Multivariable odds ratios and 95% CIs based on the derivation set are shown in Table 3. The 
model was well-calibrated (P = 0.42) and showed good discrimination (c-statistic = 0.72). 
Points given to the different values for each of the 5 variables are shown in Appendix Table 
2. The score was the sum of points for age (0 for <55 years, 1 for 55 to <60 years, 2 for 60 to 
<65 years, 3 for 65 to <70 years, or 4 for ≥70 years), sex (0 for female or 1 for male), first-
degree relative with colorectal cancer (1 for ≥1 relative or 0 for other), cigarette smoking (0 
for 0 pack-years, 2 for >0 to <30 pack-years, or 4 for ≥30 pack-years), and waist 
circumference (0 for small, 1 for medium, or 2 for large). Scores for the risk index ranged 
from 0 to 13. We computed the risk for advanced neoplasia for each score and collapsed 
scores with clinically similar risks into risk categories.
On the basis of the risk for (or prevalence of) advanced neoplasia and the risk score 
(Appendix Table 3), we identified 4 risk groups (very low, low, intermediate, and high) 
within the derivation set, with risks for advanced neoplasia that ranged from 1.92% (95% CI, 
0.63% to 4.43%) among the nearly 9% considered to be at very low risk to 24.9% (CI, 
21.1% to 29.1%) among the 15.5% who were at high risk (P < 0.001 for trend) (Table 4). 
The 1591 total persons in the very-low-risk and low-risk groups represented 53% of the 
derivation set. Five adenocarcinomas were detected in this combined subgroup, all of which 
were located in the distal colon. If this subgroup had undergone sigmoidoscopy with 
detection of any distal polyp resulting in a diagnostic colonoscopy, 51 of 70 (73% [CI, 61% 
to 83%]) advanced neoplasms would have been detected; 19 persons had advanced proximal 
adenomas without a distal sentinel lesion.
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In the validation set, the risks for advanced neoplasia were similar to those in the derivation 
subgroup, ranging from 1.65% (CI, 0.20% to 5.84%) among participants in the very-low-
risk group to 22.3% (CI, 16.9% to 28.5%) in the high-risk group (Table 4). Risk for (or 
prevalence of) advanced neoplasia for each score from 0 to 12 in the validation set is shown 
in Appendix Table 3. The 786 total persons in the very-low-risk and low-risk groups 
represented slightly more than 53% of the validation set. No cancer cases were detected in 
this combined subgroup. Further, 21 of 24 (87.5% [CI, 68% to 97%]) advanced neoplasms 
would have been detected if sigmoidoscopy had been performed with subsequent 
colonoscopy for a finding of a distal polyp.
Discussion
Colorectal cancer screening is effective and cost-effective, but it is also underused, 
potentially risky, and costly. Colonoscopy is the predominant screening test used in the U.S. 
health care system (1), even though no comparative outcomes studies have been done and 
quantitative modeling shows that alternative strategies may—when a less sensitive test is 
applied more frequently over time—be at least as effective as a colonoscopy-based strategy 
(11–12). In addition, studies of colonoscopy capacity in the United States (15, 36) and other 
countries (37) suggest that it is a limited resource (38–39). The ability to accurately and 
reliably estimate and stratify risk for colorectal cancer and advanced precancerous polyps 
among persons currently classified as average-risk could help guide choice among several 
available test options for patients and providers. In the larger picture, such risk stratification 
and resultant tailoring within the average-risk group would make screening more efficient by 
targeting colonoscopy toward higher-risk persons and away from lower-risk persons, who 
could be effectively screened with less invasive tests, all of which are recommended by the 
U.S. Preventive Services Task Force (12).
Our model identified 4 risk groups, with risk for advanced neoplasia ranging from less than 
2% among very-low-risk persons to 22% to 25% among high-risk persons. The model could 
be used to tailor screening on the basis of risk for advanced neoplasia. Persons at very low or 
low risk could be screened effectively and efficiently with strategies other than colonoscopy, 
including sigmoidoscopy every 5 years, fecal immunochemical testing annually, both 
strategies combined, or another less invasive strategy. For persons at high risk, screening 
with colonoscopy seems to be warranted. Persons at intermediate risk, who have the same 
risk as that observed in large-scale screening studies (40–41), could continue to choose from 
the available tests. Such risk-based tailored screening has the potential to increase the uptake 
and efficiency of colorectal cancer screening.
Over the past decade, several risk models for advanced colorectal neoplasia have been 
developed in the screening setting (19–20, 22, 24, 34, 42). The clinical and methodological 
variation in both model performance and extent of validation has precluded selection of any 
of them for use in decision making about colorectal cancer screening. The models vary in 
important features, including the outcome predicted (advanced neoplasia vs. advanced 
proximal neoplasia), demographic characteristics of the study population, risk factors, ability 
to achieve clinically meaningful risk stratification, degree of discrimination, and extent of 
validation. A summary of the published risk prediction models for advanced adenoma or 
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advanced neoplasia is shown in Appendix Table 4. All of the models shown have limitations 
that require consideration, including the ability to reliably and accurately measure the 
variables contained in the model, clinical importance of the magnitude of the risk gradient, 
proportion of the study population found to be at low or high risk, and applicability of the 
findings beyond the population from which the model was derived.
For the U.S. population, in which colonoscopy dominates screening (1), the model we 
describe seems to have the greatest potential for clinical application because it contains 5 
factors that can be easily and reliably measured and that are likely to be present in medical 
records. The model itself is simple to use; it was derived from and validated in a cohort of 
average-risk U.S. persons aged 50 to 80 years who were having their first screening 
colonoscopy. The model distributes persons more evenly among its risk categories than do 
other models. Also, both the degree of discrimination (as measured by the c-statistic) and the 
risk gradient are greater than those of the other models, suggesting a more robust and 
clinically meaningful separation of risk for advanced neoplasia across the 4 risk groups.
In several cross-sectional screening studies, age and sex accounted for much of the variation 
in prevalence of advanced neoplasia (28, 34, 40–41, 43–44). Our risk score may have 
particular importance among women aged 50 to 59 years, who have been identified as a low-
risk subgroup for whom screening may be performed noninvasively or possibly deferred (42, 
45). The current study included 1108 women in this age group with a 5.2% prevalence of 
advanced neoplasia, which is lower than that of the entire cohort. Application of the risk 
score to this subgroup would have categorized 85% of these women as very-low-risk or low-
risk, with risks for advanced neoplasia from the lowest- to highest-risk groups of 1.92%, 
5.02%, 11.3%, and 0%, respectively (P < 0.001). This shows that the risk score provides 
incremental discrimination within this large low-risk subgroup, for which non–colonoscopy-
based screening may be most efficient. Understanding the differences in outcomes and costs 
between tailored screening and colonoscopy for all persons, particularly in women aged 50 
to 59 years, requires formal modeling to quantify these tradeoffs (46).
Our model may have strengths compared with a similar model derived from and internally 
validated in the screening setting. Kaminski and colleagues (21) derived a model containing 
age, sex, family history of colorectal cancer, cigarette smoking, and BMI to identify low- 
and high-risk groups in nearly 36 000 persons aged 40 to 66 years who had screening 
colonoscopy (Appendix Table 4). Although the risks for advanced neoplasia in the validation 
set of 17 939 persons were 2.49% and 19.44% in the low- and high-risk groups, respectively, 
these risk extremes represented only 1% of the sample when combined, whereas in our 
model the risk extremes represented between 22.9% and 24.2%. Further, the comparability 
of this model and ours is uncertain because of differences in the physical measure used 
(BMI vs. waist circumference) and the difference in age range between the study cohorts 
(Appendix Table 4). We tested Kaminski and colleagues' model on our cohort, and its 
discrimination was inferior to that of our model (data not shown).
This study has strengths, including the relatively large sample size, uniformity of data 
collection across sites, and completeness of data collection from study participants, all of 
which allowed for a robust analysis. However, the study also has limitations. First, the 
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variables used for this model were chosen on the basis of the published literature (that is, 
they were predetermined). Other variables might have better discrimination, but we suggest 
that the performance of these variables in the validation set, using the cut points derived in 
the derivation set, is substantially stronger than in other models. A strength of using these 
variables is that they are easily measured, and all except waist circumference are likely to be 
easily identifiable from the medical record. Although other models containing a greater 
number of factors that are less easily measured may perform better, more complex models 
may be less useful from practical and clinical perspectives. Second, the prediction equation 
has imperfect discrimination; some patients with advanced neoplasia would be categorized 
as low-risk, including those with colorectal cancer. Detection of these lesions would depend 
on which less invasive strategy was used (sigmoidoscopy; fecal immunochemical or other 
stool-based testing; both tests; or other tests, such as computed tomographic colonography). 
Of note, the model quantifies the prevalence of advanced neoplasia anywhere in the 
colorectum; it does not distinguish between proximal and distal disease and therefore cannot 
determine which less invasive test may be preferred. Nonetheless, the 5 cancer cases in the 
low-risk subgroups of the derivation set were within reach of a sigmoidoscope; no cancer 
was found in the low-risk groups of the validation set. This post hoc observation, in 
particular, requires validation in independent cohorts. Use of sigmoidoscopy alone in the 
low-risk groups would have detected 73% to 87.5% of all advanced neoplasia in a single 
application. If fecal immunochemical testing were used as well, additional advanced 
neoplasms would probably have been detected. Further, because of transition rates from 
advanced adenoma to cancer of less than 3% in low-risk patients (25), subsequent screening 
with fecal immunochemical testing, sigmoidoscopy, or both would provide additional 
opportunity for detection of advanced neoplasia. Third, this model was validated using the 
split-sample method, which is a relatively simple way to test for overfitting (47–48) but does 
not determine the generalizability to independent cohorts. The transportability of the model 
beyond the type of population studied has not yet been established. Fourth, the study cohort 
comprised predominantly white persons, and whether the findings are generalizable to a 
more racially diverse population is uncertain. Although black persons are believed to be at 
higher risk for colorectal neoplasia, recent studies have shown no clinically important 
differences in prevalence of neoplasia between black and white persons (49–52). Further 
study of this issue is required. Finally, an important practical consideration of any validated 
model is quantification of its clinical and economic impact—in this case, on screening 
uptake, adherence, and efficiency. These effects remain to be determined.
In conclusion, this 5-variable risk index may help decision making about colorectal cancer 
screening for persons currently considered to be at average risk, for whom several test 
options are equally strongly recommended. The index identified both lower-risk groups that 
may be screened with strategies other than colonoscopy and a higher-risk group for which 
colonoscopy may be preferable in terms of yield and efficiency. If this index is further 
validated externally in independent cohorts, it could increase the uptake and efficiency of 
colorectal cancer screening in the United States.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Description of demographic and clinical factors in derivation and validation sets.
Variable Derivation set* Validation set
Number of individuals 3025 1475
Age (mean ± SD) 57.3 ± 6.6 years 57.2 ± 7.0 years
Women 51.6% 51.5%
Caucasian 94.6% 94.4%
First-degree relative with CRC 9.6% 9.2%
Lifetime nonsmoker‡ 60.3% 60.5%
Body mass index§ (mean ± SD) 28.6 ± 5.7 28.8 ± 5.9
Waist circumference (mean ± SD) 36.4 ± 5.3 in. 36.5 ± 5.5 in.
Advanced neoplasia 9.4% 8.5%
N (%) with complete data 2993 (98.9%) 1467 (99.5%)
*
Missing data: cigarette smoking, n=20 (0.66%); waist circumference, n=12 (0.39%)
†
Missing data: cigarette smoking, n=6 (0.41%); waist circumference, n=2 (0.14%)
‡
Defined either as never having smoked or having smoked less than 100 cigarettes lifetime.
§
Units are weight in kilograms /height in meters2
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Table 2
Age- and sex-adjusted logistic regression models of advanced neoplasia for categorical factors*
Variable Categories Odds Ratio† (95% CI) P-value
1 or more first-degree No ---
relatives with colorectal cancer Yes 1.37 (0.94 – 2.00) 0.107
Cigarette smoking Non-smoker --- <0.0001
> 0 to < 30 pack-years 2.06 (1.52 – 2.80)
≥ 30 pack-years 3.39 (2.47 – 4.66)
Waist circumference‡ Small ---
Medium 1.44 (1.11 – 1.88) 0.003
Large 2.01 (1.23 – 3.29)
*
Based on a derivation set of 2993
†
Odds ratios represent the age-and sex-adjusted odds of advanced neoplasia. An odds ratio > 1 indicated an increased risk of advanced neoplasia
‡
Small: < 37.4 inches for men, < 34.6 inches for women; Medium: 37.4–47.2 inches for men, 34.6–43.3 inches for women; Large: ≥ 47.2 inches 
for men, ≥ 43.3 inches for women
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Table 3
Multivariable regression model of advanced neoplasia and resulting scores for each variable*
Variable Odds Ratio (95% CI) Log Odds Coefficient Score
Age (per year increase) 1.06 (1.04–1.08) 0.0592 0 to 4†
Sex
 Women Reference group 0
 Men 1.69 (1.30–2.20) 0.5225 1
≥ 1 First-degree relative with colorectal cancer 1.39 (0.94–2.04) 0.3259 1
Waist circumference‡
 small Reference group 0
 medium 1.41 (1.08–1.84) 0.3426 1
 large 1.88 (1.14–3.09) 0.6313 2
Cigarette smoking
 0 pack-years Reference group
 >0 to <30 pack years 2.07 (1.52–1.84) 0.7250 2
 ≥30 pack-years 3.33 (2.43–4.58) 1.2042 4
*
Based on a derivation set of 2993
†
0 points for age < 55 years; 1 point for 55 to <60 years; 2 points for 60 to < 65 years; 3 points for 65 to <70 years; 4 points for ≥70 years
‡
Small: < 37.4 inches for men, < 34.6 inches for women; Medium: 37.4–47.2 inches for men, 34.6–43.3 inches for women; Large: ≥ 47.2 inches 
for men, ≥ 43.3 inches for women
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